Genetic Tests: Future or Fad?

They may take away my bachelor's in genetics for this, but I have to admit, I'm not interested in having a genomewide test run on my DNA. More specifically, I'm not interested in shelling out a thousand bucks to find out minute details about my genes.

Last week, deCODE genetics (Nasdaq: DCGN  ) announced that it's accepting subscriptions for its DNA testing service, deCODEme, which will test 1 million DNA variants using biochips from Illumina (Nasdaq: ILMN  ) . That's a lot of variants, but it skips the rare -- but more definitive -- traits such as mutations in BRCA1, which drastically increases the risk of developing breast cancer. Instead, the test will concentrate on genes that lead to "obvious and potentially quirky traits."

The service will compete against the recently launched service from 23andMe, which has backing from Google (Nasdaq: GOOG  ) and Genentech (NYSE: DNA  ) . Both companies have a Web 2.0 aspect in that you can share your genetic information among family and friends on the companies' websites. Learning about one's ancestry may be the potential driver of new customers for the foreseeable future, and the late-November launches were probably an effort to get rich Aunt Mildred to buy genetic tests for everyone for Christmas.

While I think this information is interesting, I'm just not sure these tests will become wildly popular until their prices come down. Investors looking to invest in genetic tests would be better off investing in companies -- like Rule Breakers pick Myriad Genetics (Nasdaq: MYGN  ) , Genzyme (Nasdaq: GENZ  ) , or even deCODE -- that offer tests for specific diseases that might run in an individual's family. As medicine gets more personal, specific genetic tests will have a lot more value to patients than genomewide tests.

More Foolishness about DNA:

Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 540437, ~/Articles/ArticleHandler.aspx, 10/24/2016 6:01:40 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,223.03 77.32 0.43%
S&P 500 2,151.33 10.17 0.47%
NASD 5,309.83 52.43 1.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

1/5/2010 3:59 PM
DCGN $0.07 Down +0.00 +0.00%
deCODE Genetics CAPS Rating: ***
DNA $94.97 Down +0.00 +0.00%
Genentech CAPS Rating: ****
GENZ.DL $76.25 Down +0.00 +0.00%
Genzyme Corp CAPS Rating: ****
GOOGL $835.74 Up +11.68 +1.42%
Alphabet (A shares… CAPS Rating: *****
ILMN $142.27 Up +0.47 +0.33%
Illumina CAPS Rating: *****
MYGN $19.70 Down -0.02 -0.10%
Myriad Genetics CAPS Rating: ****